Sherene Loi, MD· @LoiSher · X·· 1 天前评分70
正文 · 原文
#ESMO2026
PostMonarch - change to Fulvestrant v placebo with Abema- continues to show better PFS and OS
➡️ results by ESR1 status eagerly awaited!
#ESMOAmbassadors @OncoAlert
Published online in @Annals_Oncology
150 浏览 · 5 赞 · 4 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org来源：Sherene Loi, MD · x.com